MOUNTLAKE TERRACE, Wash., Oct. 23, 2026 (GLOBE NEWSWIRE) — FS Bancorp, Inc. (NASDAQ: FSBW) (the “Company”), the holding company for 1st Security Bank of Washington (the “Bank”), today announced that Matthew D. Mullet had been appointed to serve on the Boards of Directors of both the Company and the Bank. The Company’s Governance Nominating and Culture Committee proposed Mr. Mullet’s appointment to the Company’s Board and the Board of Directors ratified and approved the appointment. His appointment to the Board of Directors was effective October 22, 2026. “We are pleased to welcome Matt to our Board of Directors,” said Ted A. Leech, Chairman of the Board. His extensive leadership experience across all areas of banking along with his deep understanding of financial services, loan and deposit strategies, regulatory expertise, operations,...

Results presented at ESMO show a promising therapeutic index for [212Pb]VMT-α-NET Durable disease control in all three cohorts and 72% PFS at 18 months across all patients who received at least one treatment Robust activity observed at three dose levels across patient populations, with ORRs of 33% and 50% in Cohorts 2 and 3, respectively; higher responses were observed in Cohort 3 relative to Cohort 2 at early assessments [212Pb]VMT-α-NET continues to be well-tolerated, with no DLTs, and no discontinuations due to adverse events Aiming to complete Phase 3 site start-up preparations around year-end 2026, positioning us to rapidly activate clinical sites following regulatory alignment Conference call to be webcast today at 2 pm EDT / 8 pm CEST (join here)SEATTLE, Oct. 23, 2026 (GLOBE NEWSWIRE) — Perspective Therapeutics, Inc....

Equinor Energy AS has exercised one year option for the PSV vessels Havila Charisma and Havila ForesightFollowing the exercise, Havila Charisma has contract until 16 December 2027, Havila Foresight until 1 January 2028. Contacts:Chief executive officer Njål Sævik. +47 909 35 722Chief financial officer Arne Johan Dale, +47 909 87 706 This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act

Pursuant to the out-of-court settlement agreement concluded between AS Tallinna Vesi and Tallinn University of Technology on 9 October 2026, the Supreme Court of Estonia (Riigikohus) today accepted the application for waiver of the claim filed by Tallinn University of Technology on 12 October 2026 in civil case No. 2-22-10417, set aside the judgments previously rendered in the matter by the lower courts, and terminated the proceedings.  In the view of Tanel Kalaus, legal representative of Tallinna Vesi, today’s ruling is an important and most welcome step towards final resolution, which would allow all parties to devote their energy to their core activities rather than to litigation. “Although this particular dispute began as early as 2022 (and other similar disputes a couple of years earlier still), it had not progressed beyond the interim...

AUSTIN, Texas, Oct. 23, 2026 (GLOBE NEWSWIRE) — XBiotech Inc. (NASDAQ: XBIT) today announced that its Board of Directors have elected Jan-Paul Simard to serve as Co-Chief Executive Officer alongside CEO Dr. Sushma Shivaswamy, effective Oct. 23, 2026. “On behalf of the Board of Directors, we are excited to announce Dr. Sushma Shivaswamy and Jan-Paul Simard as Co-Chief Executive Officers,” said Director Tevi Troy. “Their complementary skill sets, scientific acumen, and shared commitment to our mission position XBiotech to fully realize the potential of our True-Human antibody therapies.” Dr. Shivaswamy has been with XBiotech for 17 years, having served as Senior Scientist, Director and Vice President of Research & Development prior to her appointment as Chief Scientific Officer in 2017. As CSO, Dr. Shivaswamy oversaw scientific...

ROUGEMONT, Quebec, Oct. 23, 2026 (GLOBE NEWSWIRE) — Lassonde Industries Inc. (TSX: LAS.A) (“Lassonde” or the “Corporation”) is pleased to announce that it will host a conference call to discuss its financial results for the third quarter of 2026 on Friday, November 6, 2026. Mr. Vince Timpano, Chief Executive Officer, and Mr. Francis Trudeau, Chief Financial Officer, will host the call.OPEN TO: Investors, analysts, and all interested parties   DATE: Friday, November 6, 2026   TIME: 9 a.m. ET   CALL: 416-945-7677 (for overseas participants)1-888-699-1199 (for other North American participants)A live audio broadcast of the conference call will be available on the Corporation’s website, on the Investors page or here: https://www.gowebcasting.com/15002. The replay of the webcast will remain...

Durable responses observed across multiple tumor types during dose escalation MGC026 demonstrated 27% best overall response rate (6/22 patients; 4 confirmed and 2 unconfirmed PRs) in heavily pretreated SCCHN patients MGC026 demonstrated manageable safety and tolerability profile with no treatment-related discontinuations in SCCHN patients Plan to initiate front-line SCCHN cohort evaluating MGC026 in combination with pembrolizumabROCKVILLE, MD, Oct. 23, 2026 (GLOBE NEWSWIRE) — MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced positive interim data from its Phase 1 study evaluating MGC026, a B7-H3-directed antibody-drug conjugate (ADC), in patients with advanced solid tumors. These Phase 1 data were...